Diagnostic accuracy of sinus tachycardia as an independent clinical indicator among different COVID-19 variants

MAHMOUD ELAMARY1,2, A, D, E, FAHAD KHAMIS ALOMARI1,3, A, F, AHMED NEWERA1,4, C, E, EHAB SELIM1, A, D, MARJORIE CAJUCOM MANALUS5,6, B, JAZZELLE MAHRIZ C. LAURETA7,8, EMAN ESMAAT TOSSON8, D, E

1 Department of Family Medicine, Prince Sultan Military Hospital, Taif, Saudi Arabia
2 Membership of General Practitioner (MRCGP INT), Royal college of general practitioner, London, United Kingdom
3 Arab Board of Family Medicine, Saudi Board of Family Medicine, Riyadh, Saudi Arabia
4 Department of Social and Preventive Medicine, University of Malaya, Kuala Lumpur, Malaysia
5 Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
6 Department of Nursing, University of Perpetual Help System Philippines, Binan, Philippines
7 Department of Nursing, University of La Salette, Santiago, Isabla, Philippines
8 Department of Family Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt


Summary

Background. The most common arrhythmia which have been reported frequently in COVID-19 patients is sinus tachycardia. As COVID-19 is usually misdiagnosed with other respiratory tract diseases, introduction of a rapid clinical indicator for out of proportional sinus tachycardia in the diagnosis of COVID-19 during the early viral replication stage is essential for better cost-effective use of resources.

Objectives. This study was conducted to determine the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19.

Material and methods. This is a cross-sectional analytical study. It included 152 healthcare workers who fulfilled the inclusion criteria. Multiple logistic regression analysis was conducted to investigate the factors associated with COVID-19 among the entire study sample and among each group.

Results. Among our participants, 32.9% were male, while 67.1% were female, with a mean age of 35.47 ± 7.09 years. It was found that 51.3% of our sample were COVID-19 PCR positive, and the mean number of days of symptoms at presentation was 2.01 ± 1.29. It was found that was prevalence of out of proportional sinus tachycardia among the participants diagnosed with COVID-19 in 2021 was triple that of the participants who were recruited in 2020 (61%, 26%, respectively). It was found that there was significant association between pulse rate and COVID-19, with gender, age, temperature or days of symptoms having no effect.

Conclusions. The study highlights the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19, especially the Omicron variant, as a higher pulse rate is associated with higher odds of having COVID-19.

Key words: sinus tachycardia, COVID-19, cardiac arrhythmias.


Background

At the end of 2019, a novel coronavirus was identified as the cause of pneumonia cases in Wuhan, China, which rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other countries throughout the world [1]. This first outbreak of the novel coronavirus was declared a public health emergency of international concern by the World Health Organization on 30 January [2] and a global pandemic on 11 March 2020 [1]. The COVID-19 pandemic spread rapidly around the world, including Saudi Arabia, which led to a severe health emergency [3].

Different variants of COVID-19 have been discovered worldwide, the latest variant being SARS-CoV-2 Omicron (B.1.1.529), which is the most heavily muted strain discovered so far in one of the provinces in South Africa on 24 November 2021 and has been declared by the World Health Organization (WHO) as the fifth Variant of Concern (VOC) after the Alpha, Beta, Gamma, and Delta variants on 26 November 2021 [4].

Following South Africa, more than 150 countries had been detected with the Omicron variant as of 20 January 2022 [5], and the United Kingdom reported the first known death of a patient with the Omicron variant [6]. Among patients with symptomatic COVID-19, cough, myalgias and headache are the most commonly reported symptoms. Other features, including diarrhea, sore throat and abnormalities concerning smell or taste, have also been described. Mild upper respiratory symptoms (e.g. nasal congestion, sneezing) appear to be more common.
with the Omicron variant [7], whereas low oxygen saturation, abnormal pulse rates and shortness of breath are frequently reported symptoms for the Delta variant [8]. Although COVID-19 symptoms due to the Omicron variant are milder so far, this could potentially raise death rates as it is highly contagious [9].

Studies concerning the accuracy of signs and symptoms showed that a combination of ≥ 2 symptoms/signs (fever, cough, anosmia, dyspnoea, oxygen saturation < 93%, headache) results in a highly sensitivity model for quick and accurate diagnosis of COVID-19 [10]. Early studies suggest that COVID-19 is associated with a high incidence of cardiac arrhythmias. Severe acute respiratory syndrome due to COVID-19 may cause injury to cardiac myocytes, leading to myocarditis, and may increase the risk of arrhythmia [11]. Myocarditis is an inflammatory disease of the heart which occurs due to inflammatory infiltrates and myocardial injury without an ischemic cause [12]. The most common cause of myocarditis in the United States and other developed countries is viral infection [13]. The most common arrhythmia overall in patients with COVID-19 is sinus tachycardia, but the most likely pathologic arrhythmias include atrial fibrillation, atrial flutter and monomorphic or polymorphic ventricular tachycardia [14]. Sinus tachycardia can occur as an attribution to elevated temperature in adults (approximately 8.5 beats/minute for every 1°C elevation in oral temperature above 37.8°C) [15, 16]. If fever is felt to be the cause of tachycardia, then the elevated heart rate should resolve when the temperature returns to normal, and this should point towards another reason for sinus tachycardia other than fever in individuals who present with tachycardia and who are afebrile, even if there was recent history of fever [17]. Few studies have fully described the diagnostic accuracy of sinus tachycardia as a clinical indicator for suspected COVID-19, and no comparison has been made in this field between different COVID-19 variants [18].

Considering that the specificity and sensitivity of signs and symptoms of different COVID-19 variants help direct the patient towards appropriate covid testing, especially as the new emerging Omicron variant is very similar to many respiratory tract infections, the more accurate a clinical indicator to suspect covid is, the less unnecessary testing will be done.

Furthermore, we do not have enough epidemiological data regarding the addition of sinus tachycardia out of proportion to fever to the classical criteria used to differentiate between the Omicron variant and other COVID-19 variants. Finally, considering the important role of family physicians, who are the first points of contact with patient within the healthcare system, rapid identification and diagnosis of patients with different COVID-19 variants is important for proper management and to prevent any cardiac complications. Thus, this research was conducted to determine the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19 and to compare our results between two different time points among different COVID-19 variants.

Objectives

This study aimed to determine the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19 and to compare our results between two different time points among different COVID-19 variants.

Material and methods

Study design

A cross-sectional analytical study was conducted to determine the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19 and to compare our results to compare our results between two different time points among different COVID-19 variants.

Study participants

The study was conducted on 152 healthcare workers, either medical or paramedical, who fulfilled the inclusion criteria and were attending the clinic assigned for clinical consultation of health care worker who were employed in Prince Sultan Military Hospital, Taif.

Setting

Recruitment took place at the clinic assigned for clinical consultation of health care worker who were employed in Prince Sultan Military Hospital, Taif, at two different time points from 23/12/2021 to 13/1/2022 and from 15/5/2020 to 31/11/2020.

Al-Taif is located in the south-eastern part of the Western Providence of Saudi Arabia, located at an elevation of 1,800 metres above sea level on the eastern slopes of the Al Sarawat Mountains, with a population of 1,083,693. Taif is 100 km from the city of Makkah, which is the most revered holy place of the international Muslim community, receiving more than 3 million visitors annually embracing the rituals of the Hajj pilgrimage.

Inclusion criteria

All eligible adult patients (≥ 18 years of age) of both gender with symptoms of suspected mild COVID-19 who were sent for home isolation or to a community quarantine facility without the need for admission within the specific duration whose medical data was fully documented were included. We selected cases with mild disease to avoid any significant confounders, such as cardiovascular complications of moderate or severe COVID-19 which may cause significant tachycardia and could interfere with our results.

Exclusion criteria

Patients whose medical records were not fully documented or triaged, any admitted patient or patients who suffered from any comorbidities such as hyperthyroidism, any cardiac disease, anaemia or those taking any concomitant drugs having an effect on heart rate (i.e. beta-blockers, antiarrhythmic, ivabradine and/or digoxin) and which could interfere with our results were excluded from our sample.

Sampling

Sample size

To obtain a confidence interval (CI) of 95% and a 5% margin of error, a sample size of 156 participants was required.

Sample technique

Convenience sampling was used to select equivalent numbers (78 electronic medical record) of patients from each of the two different time point from 23/12/2021 to 13/1/2022 and from 15/5/2020 to 31/11/2020.

Data was first collected from 23/12/2021 to 13/1/2022 by reviewing the electronic medical records of patients who attended the employee health clinic of the Family Medicine Department, Prince Sultan Hospital, Taif, with symptoms of suspected COVID-19. An equivalent number of the electronic medical records of patients from 15/5/2020 to 31/11/2020 were then reviewed retrospectively; however, the collection of our sample took much more time than expected (nearly 6 months) in comparison to the 1 month taken in the first step. This can be
explained due to the fact that in order to reach an equivalent number to our cases in first step, the duration of sample collection had to be extended to 6 months, as the incidence rate of the pandemic was low in contrast to the high incidence rate at the outbreak of the Omicron variant.

The electronic medical records were reviewed to collect data concerning age, gender, the onset date of COVID-19 symptoms and signs, days of symptoms at presentation, past medical history, systolic and diastolic Blood Pressures (BP), body temperature in degrees Celsius and laboratory exams at the time of attendance.

The patients included in our research were classified into 4 groups according to their COVID-19 result by Real Time PCR and the presence or absence of tachycardia as follows:

Group A – Those who had a negative result by RT COVID-19 PCR, and their pulse on attendance was ≤ 100 beats/minute.

Group B – Those who had a negative result by RT COVID-19 PCR, and their pulse on attendance was > 100 beats/minute.

Group C – Those who had a positive result by RT COVID-19 PCR, and their pulse on attendance was ≤ 100 beats/minute.

Group D – Those who had a positive result by RT COVID-19 PCR, and their pulse on attendance was > 100 beats/minute.

• In our sample, patients who had tachycardia > 100 beats/minute associated with fever (oral temperature above 37.8°C) either had COVID-19 or were not validated against the standardised-based evidence equation to determine if pulse was increased out of the proportion to fever or not [15, 16]. Patients with sinus tachycardia proportional to fever were excluded from the data which underwent analysis (4 patients total, 3 were excluded from the participants who were selected in 2020, and 1 patient was excluded from the participants who were selected in 2021). Statistical analysis was carried out on 152 participants.

• Any patients included in group D (those who had a positive result by RT COVID-19 PCR, and their pulse on attendance was > 100 beats/minute) were routinely investigated after recovery (10 days after positive PCR result, as recommended by the COVID-19 management protocol in KSA) to exclude any cardiac complications for the following:
  - Pulse re-examination to confirm a baseline pulse.
  - ECG, to ensure that there was no abnormality in ECG after recovery nor any signs of pericarditis or myocarditis.
  - ESR and CRP, to exclude any possibility of active inflammatory processes.
  - CBC and TSH, to rule out other common causes of tachycardia such as anaemia or hyperthyroidism.

The sensitivity, specificity, ROC curve, negative predictive value and positive predictive value of sinus tachycardia were calculated for the patients who attended in late 2021 and early 2022, as well as the patients who attended in 2020, and both results were compared.

The result of 2020 is believed to be reflective of the accuracy of tachycardia as a clinical indicator of COVID-19 among the participants diagnosed with COVID-19 in 2021 was triple that of the participants who were recruited in 2020 (61%, 26%, respectively). The mean temperature in our sample was 36.99 ± 0.58°C. Among our participants, 51.3% were COVID-19 PCR positive, and the mean number of days of symptoms at presentation was 2.01 ± 1.29 (Table 1).

Multiple logistic regression analysis was conducted to investigate the factors associated with COVID-19 among all the study samples, and it was found that there was significant association between pulse rate and COVID-19, with gender, age, temperature or days of symptoms having no effect. A higher pulse rate is associated with higher odds of having COVID-19 (OR = 1.04, 95% CI: 1.02–1.07, p < 0.05) (Table 2).

Table 3 shows the results of multiple logistic regression analysis, which studied the association between pulse rate and COVID-19 among each group. It was observed that there was no significant association between pulse rate and COVID-19 among the participants who were recruited in 2020, while there was a significant association between pulse rate and COVID-19 among the participants who were recruited in 2021–2022, with gender, age, temperature or days of symptoms having no effect. A higher pulse rate is associated with higher odds of having COVID-19 (OR = 1.09, 95% CI: 1.04–1.14, p < 0.001).

Nomogram analysis was conducted to investigate whether pulse rate is a predictor for the probability of having COVID-19, and it was found that there was direct relationship between pulse rate and the probability of having COVID-19 among all the study samples (Figure 1).
Table 1. Personal and clinical characteristics of the study samples (n = 152)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Male n (%)</th>
<th>Female n (%)</th>
<th>Mean, SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>50</td>
<td>102</td>
<td>35.47, 7.09</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group</td>
<td>2020 n (%)</td>
<td>2021–2022 n (%)</td>
<td>78</td>
</tr>
<tr>
<td>Pulse rate</td>
<td>mean, SD</td>
<td></td>
<td>94.52, 16.01</td>
</tr>
<tr>
<td>Prevalence of out of proportional sinus tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in all study samples (152)</td>
<td>2020 n (%)</td>
<td>2021–2022 n (%)</td>
<td>20</td>
</tr>
<tr>
<td>Prevalence of out of proportional sinus tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in COVID-19 positive patients</td>
<td>2020 n (%)</td>
<td>2021–2022 n (%)</td>
<td>10</td>
</tr>
<tr>
<td>Temperature</td>
<td>mean, SD</td>
<td></td>
<td>36.99, 0.58</td>
</tr>
<tr>
<td>Days of symptoms at presentation</td>
<td>mean, SD</td>
<td></td>
<td>2.01, 1.29</td>
</tr>
<tr>
<td>COVID-19 PCR result among all study samples (152)</td>
<td>(2020) n</td>
<td>(2021) n</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>negative n</td>
<td>positive n</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>75</td>
<td>77</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Multiple logistic regression for the association between pulse rate and COVID infection among all study samples (n = 152) controlling for other variables

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Unadjusted OR</th>
<th>Adjusted OR</th>
<th>95% CI of OR</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female)</td>
<td>1.08</td>
<td>0.97</td>
<td>0.47</td>
<td>1.99</td>
</tr>
<tr>
<td>Age</td>
<td>1.00</td>
<td>1.00</td>
<td>0.96</td>
<td>1.05</td>
</tr>
<tr>
<td>Temperature</td>
<td>1.28</td>
<td>0.89</td>
<td>0.47</td>
<td>1.66</td>
</tr>
<tr>
<td>Days of symptoms at presentation</td>
<td>0.86</td>
<td>0.92</td>
<td>0.70</td>
<td>1.20</td>
</tr>
<tr>
<td>Pulse rate</td>
<td>1.04</td>
<td>1.04</td>
<td>1.02</td>
<td>1.07</td>
</tr>
</tbody>
</table>

*Statistically significant at p < 0.05.

Table 3. Multiple logistic regression for the association between PR and COVID infection for each group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>2020 (n = 75)</th>
<th>2021–2022 (n = 77)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>p</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>0.74</td>
<td>0.28–1.92</td>
</tr>
<tr>
<td>Age</td>
<td>1.05</td>
<td>0.98–1.13</td>
</tr>
<tr>
<td>Temperature</td>
<td>0.87</td>
<td>0.40–1.87</td>
</tr>
<tr>
<td>Days of symptoms at presentation</td>
<td>0.93</td>
<td>0.620–1.39</td>
</tr>
<tr>
<td>Pulse rate</td>
<td>0.99</td>
<td>0.96–1.03</td>
</tr>
</tbody>
</table>

*Statistically significant as p < 0.05.

Figure 1. Nomogram for pulse rate as a predictor for the probability of having COVID-19 infection among all the study samples (n = 152)

Figure 2. Nomogram for pulse rate as a predictor for the probability of having COVID-19 infection among the study samples who were recruited in 2021–2022 (n = 77)
Figure 2 clarifies that the probability of having COVID-19 was increased by increasing pulse rate.

Figure 3 showed the results of a scatter plot analysis studying the association between pulse rate and temperature segregated by COVID-19 status among participants who were recruited in 2020, and it was observed that there was positive association between pulse rate and temperature for negative COVID-19 cases only. On the other hand, the association between pulse rate and temperature segregated by COVID-19 status among participants who were recruited in 2021 is presented in Figure 4, which shows a positive relationship between pulse rate and temperature for both positive and negative COVID-19 cases. However, the fit line for positive cases is higher than that for negative cases (higher intercept). This means that positive COVID-19 cases have higher pulse rates when compared to the negative COVID-19 cases.

Finally, the results of the Area under the ROC curve (AUC) analysis are summarised in Table 4, and it was found that there was statistically significant association between pulse rate and having COVID-19 among the participants who were recruited in 2021 ($p < 0.001$).

Table 5 shows the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19 based on the Youden index among participants who were recruited in 2021, and it was found that sinus tachycardia had high sensitivity, specificity, positive and a negative predictive value (75%, 84%, 83%, 76%, respectively).

**Table 4. Area under the ROC curve (AUC)**

<table>
<thead>
<tr>
<th></th>
<th>All data</th>
<th>2020</th>
<th>2021–2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area under the ROC curve (AUC)</td>
<td>0.683</td>
<td>0.509</td>
<td>0.834</td>
</tr>
<tr>
<td>95% Confidence interval</td>
<td>0.603 to 0.756</td>
<td>0.390 to 0.626</td>
<td>0.732 to 0.909</td>
</tr>
<tr>
<td>$p$</td>
<td>&lt; 0.001</td>
<td>0.901</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

**Table 5. Cut off point based on the Youden index (for 2021–2022)**

<table>
<thead>
<tr>
<th></th>
<th>value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cut off point</td>
<td>&gt; 96</td>
<td></td>
</tr>
<tr>
<td>Sensitivity</td>
<td>75.00</td>
<td>58.8–87.3</td>
</tr>
<tr>
<td>Specificity</td>
<td>83.78</td>
<td>68.0–93.8</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>83.3</td>
<td>70.2–91.4</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td>75.6</td>
<td>64.0–84.4</td>
</tr>
</tbody>
</table>

**Discussion**

The present study was conducted to determine the diagnostic accuracy of sinus tachycardia as an independent indicator of COVID-19 and to compare our results between two different time points among different COVID-19 variants. Among the 152 electronic medical records of patients with symptoms of suspected mild COVID-19 who were enrolled in the current study, 50 were male (32.9%), and 102 were female (67.1%), with the mean age
being 35.47 ± 7.09 years. The mean pulse rate among our recruit-
sampled was 94.52 ± 16.01 beats per minute, and the mean
temperature was 36.99 ± 0.58°C. Among our participants, 51.3% were
COVID-19 PCR positive, with the mean number of days of symp-
toms at presentation being 2.01 ± 1.29.

In the current study, it was found that the prevalence of out of proportional sinus tachycardia among the participants diagnosed with COVID-19 in 2021 was triple that of the participants who were recruited in 2020 (61%, 26%, respectively). As previously mentioned, the result from 2020 is believed to be reflective of the accuracy of tachycardia as a clinical indicator of COVID-19 for predominant variants in Saudi Arabia at that time, which is believed to be the SARS-COV-2 wild type, as the first variant of concern (Alpha variant) was designated on 14/12/2020 [19], while the result of 2021–2022 is believed to be reflective of the accuracy of tachycardia as a clinical indicator of COVID-19 during the surge of cases after the discovery of first Omicron case on 1/12/2021 in Saudi Arabia [20].

Our results were consistent with the findings of Jia He et al., who conducted a case report to study characteristic electrocardiographic manifestations in patients with COVID-19 and who reported that sinus tachycardia is the most common ECG finding in COVID-19 patients [21].

Our findings were in agreement with the results of a pro-
spective observational study conducted by Jae Hyung Cho et al. in the western United States to investigate cardiac arrhythmias in hospitalised patients with COVID-19, and they declared that sinus tachycardia was the most common arrhythmia detected in 39.9% (57 out 143) of their patients [22].

In the present research, multiple logistic regression analysis was conducted to investigate factors associated with COVID-19 among the entire study sample, and it was found that there was significant association between pulse rate and COVID-19, with gender, age, temperature or days of symptoms having no effect. A higher pulse rate is associated with higher odds of having COVID-19 (OR = 1.04, 95% CI: 1.02–1.07, p = 0.001).

These findings were compatible with the findings that were published concerning stealth Omicron symptoms on 15 March 2022 and which found that a higher pulse rate is associated with a higher probability of having COVID-19, especially the Omicron variant [23].

Furthermore, our findings were consistent with the results of a study that was conducted by Trevano et al., who found that heart rate is a simple and quick way to evaluate sympathetic activity. Although some concern remains on its capacity to discern between different components of the autonomic nervous system, it can be used for a first screening [24].

On the other hand, our findings were inconsistent with the findings of a study that was conducted by Alessandro Maloberti et al., who assessed the prevalence of elevated heart rate upon discharge in patients hospitalised for COVID-19, and they declared that a high heart rate at discharge (> 100 bpm, i.e. sinus tachycardia) in COVID-19 patients is not such a frequent problem, as it only involved 5.5% of their population. On the other hand, they reported that the presence of sinus tachycardia seemed to be strongly related to evidence of a severe course of disease [25].

At the best of our knowledge, our research to study the di-
gnostic accuracy of sinus tachycardia as an independent indi-
cator of COVID-19 disease, especially the Omicron variants, is novel and no paper has been published regarding this topic yet.

Limitations of the study

There may be some possible limitations in this study. For example, the small sample size and sampling bias, where the selected participants may not represent the real population under study, may affect the generalisation of the results. Additionally, no long-term data regarding heart rate following discharge is available, and thus we cannot answer the question regarding how long this problem persists over time in patients suffering from out of proportional sinus tachycardia.

Conclusions

The study highlights the diagnostic accuracy of sinus tachy-
cardia as an independent indicator of COVID-19, especially the Omicron variant. It was found that a higher pulse rate is associated with higher odds of having COVID-19.

Source of funding: This work was funded from the authors’ own resources.

Conflicts of interest: The authors declare no conflicts of interest.

References


